{"entity":{"id":"ripk2","kind":"target","name":"RIPK2","aka":["receptor interacting serine/threonine kinase 2","RIP2","RICK"],"tldr":"RIPK2 relays alarm signals from the NOD1 and NOD2 sensors that detect bacteria, switching on inflammation. It has been proposed as a cancer target both for its effects on immune cells and, in prostate cancer, for helping tumours spread; a RIPK2 inhibitor is in an early melanoma trial.","summary":"RIPK2 (chromosome 8q21.3) is a kinase that is the key effector of the NOD1 and NOD2 bacterial sensors: once recruited it is polyubiquitinated and becomes a scaffold for downstream signalling, modulating innate and adaptive immune responses (UniProt O43353). A 2022 Nature Communications study reported RIPK2 amplified or gained in about 65% of lethal metastatic castration-resistant prostate cancers, found that it stabilises c-Myc through MKK7, and showed that its knockout or inhibition reduced prostate cancer metastasis in models (Yan et al., doi:10.1038/s41467-022-28340-6). In OnCo, OPM-101 is an oral RIPK2 inhibitor that blocks the NOD2/RIPK2 pathway, which its developer says is designed to reprogram immune responses in cancer, in a phase 1 trial in melanoma.","asOf":"2026-11-03","links":[{"label":"HGNC HGNC:10020","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10020"},{"label":"UniProt O43353","url":"https://www.uniprot.org/uniprotkb/O43353/entry"},{"label":"NCBI Gene 8767","url":"https://www.ncbi.nlm.nih.gov/gene/8767"},{"label":"RIPK2 stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis (Nat Commun 2022)","url":"https://doi.org/10.1038/s41467-022-28340-6"}],"tags":["pipeline-gap-target"],"related":[],"cancers":["prostate-mcrpc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["opm-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC, UniProt and the paper cited give no positivity rate."],"provenance":{"editedBy":"OnCo gap audit, class 5 targets (HGNC REST, UniProt REST, Europe PMC, corpus drug records)","editedOn":"2026-11-03"},"symbol":"RIPK2","role":["drug-target"],"sources":[],"specificitySources":[],"hgnc":"HGNC:10020","ensembl":"ENSG00000104312","uniprot":"O43353","entrez":"8767","biology":"Serine/threonine/tyrosine kinase recruited to NOD1 and NOD2 through CARD-CARD interaction; it forms filaments and is polyubiquitinated by XIAP, BIRC2, BIRC3 and LUBAC, becoming a scaffold for downstream signalling (UniProt O43353).","whereFound":["Metastatic castration-resistant prostate cancer (amplified or gained in about 65%, doi:10.1038/s41467-022-28340-6)","Melanoma (OPM-101 trial)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/ripk2/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"opm-101","kind":"drug","name":"OPM-101","route":"/drugs/opm-101/"}]}}